You can not change a tiger into a kitten by stroking it." - Franklin Delano Roosevelt
Today, we look at a name that has a presentation at the 21st Annual Meeting The American Society of Gene and Cell Therapy that's taking place in Chicago from Wednesday through Saturday this week. Positive data could continue to be a catalyst for the stock. Investors seem to be anticipating this a bit as the stock is running up this week into this presentation. We take a look at this "Tier 4" biotech concern in the paragraphs below.
Company Overview:
Voyager Therapeutics (VYGR) is a Massachusetts-based concern that came public late in 2015. The stock currently has an approximate market cap of just south of $650 million and sells for around $20.00 apiece after this week's early rally. The company is focused on progressing its promising gene therapy candidates through the clinic to commercialization and has chosen as an area of focus neurological diseases that lack safe, effective treatment options.
Top Biotech Stocks To Watch For 2019: NetApp Inc.(NTAP)
Advisors' Opinion:- [By Motley Fool Staff]
NetApp, Inc. (NASDAQ:NTAP)Q4 2018 Earnings Conference CallMay 23, 2018, 5:00 p.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
- [By Joseph Griffin]
NetApp (NASDAQ:NTAP) was upgraded by research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Friday.
- [By ]
On the earnings call, CFO Jim Kavanaugh called IBM's storage performance "disappointing," and blamed a mixture of competition, price pressure and sales execution issues. Rivals such as HP Enterprise (HPE) and NetApp (NTAP) have been reporting stronger storage growth, as industry demand benefits from an Intel (INTC) server CPU upgrade cycle.
Top Biotech Stocks To Watch For 2019: Cogentix Medical, Inc.(CGNT)
Advisors' Opinion:- [By Joseph Griffin]
News coverage about Vision Sciences (NASDAQ:CGNT) has trended somewhat positive on Friday, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vision Sciences earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave news headlines about the medical device company an impact score of 43.7920504117832 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Top Biotech Stocks To Watch For 2019: First Cash Financial Services, Inc.(FCFS)
Advisors' Opinion:- [By Logan Wallace]
First Cash Financial Services, Inc. (NYSE:FCFS) shares hit a new 52-week high and low during trading on Thursday . The company traded as low as $88.95 and last traded at $88.70, with a volume of 371494 shares traded. The stock had previously closed at $87.80.
- [By Joseph Griffin]
First Cash Financial Services (NYSE: FCFS) and Ferrellgas Partners (NYSE:FGP) are both finance companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.
- [By Stephan Byrd]
Get a free copy of the Zacks research report on First Cash Financial Services (FCFS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment